Bernard Royer

1.8k total citations
68 papers, 1.2k citations indexed

About

Bernard Royer is a scholar working on Oncology, Surgery and Molecular Biology. According to data from OpenAlex, Bernard Royer has authored 68 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Oncology, 15 papers in Surgery and 15 papers in Molecular Biology. Recurrent topics in Bernard Royer's work include Intraperitoneal and Appendiceal Malignancies (10 papers), Renal Transplantation Outcomes and Treatments (8 papers) and Ovarian cancer diagnosis and treatment (8 papers). Bernard Royer is often cited by papers focused on Intraperitoneal and Appendiceal Malignancies (10 papers), Renal Transplantation Outcomes and Treatments (8 papers) and Ovarian cancer diagnosis and treatment (8 papers). Bernard Royer collaborates with scholars based in France, United States and Belgium. Bernard Royer's co-authors include Jean‐Pierre Kantelip, Siamak Davani, B Kantelip, Michel Arock, Joseph-Philippe Etievent, Patrick Hervé, Aliette Marandin, Philippe Saas, J J Guillosson and Antonin Schmitt and has published in prestigious journals such as Circulation, Journal of Clinical Oncology and PLoS ONE.

In The Last Decade

Bernard Royer

65 papers receiving 1.1k citations

Peers

Countries citing papers authored by Bernard Royer

Since Specialization

Citations

This map shows the geographic impact of Bernard Royer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bernard Royer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bernard Royer more than expected).

Fields of papers citing papers by Bernard Royer

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bernard Royer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bernard Royer. The network helps show where Bernard Royer may publish in the future.

Co-authorship network of co-authors of Bernard Royer

This figure shows the co-authorship network connecting the top 25 collaborators of Bernard Royer. A scholar is included among the top collaborators of Bernard Royer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bernard Royer. Bernard Royer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Impact of gastrectomy on cabozantinib exposure: Clinical case of a patient with clear renal cell carcinoma 2025 ·Clinical Genitourinary Cancer ·(unknown), (unknown), Antonin Schmitt, Bernard Royer, Philippe Barthélémy	0
2	Beneficial effect of resveratrol on T cell oxidative metabolism and anti-tumor function is conditioned by prior in vivo T cell history 2025 ·Molecular Therapy — Methods & Clinical Development ·(unknown), (unknown), Bernard Royer, Paul Peixoto, Barbara Dehecq, Olivier Adotévi, Jeanne Galaine, Yann Godet	1
3	Plasma clearance of 5-fluorouracil is more influenced by variations in glomerular filtration rate than by uracil concentration 2024 ·Cancer Chemotherapy and Pharmacology ·(unknown), (unknown), (unknown), (unknown), François Ghiringhelli, Leïla Bengrine-Lefèvre, (unknown), Françoise Goirand, Bernard Royer, Antonin Schmitt	2
4	Case report: 5-Fluorouracil treatment in patient with an important partial DPD deficiency 2023 ·Frontiers in Oncology ·Antonin Schmitt, Bernard Royer, Romain Boidot, (unknown), François Ghiringhelli	2
5	Pharmacokinetics and Pharmacodynamic of Alpelisib 2023 ·Clinical Pharmacokinetics ·Bernard Royer, Courèche Kaderbhaï, Antonin Schmitt	7
6	Quantitative impact of pre‐analytical process on plasma uracil when testing for dihydropyrimidine dehydrogenase deficiency 2022 ·British Journal of Clinical Pharmacology ·(unknown), Manon Launay, Bernard Royer, Jérôme Guitton, Elodie Gautier‐Veyret, Sophie Broutin, Camille Tron, (unknown), Joseph Ciccolini, Damien Richard, (unknown), Vincent Haufroid, (unknown), Antonin Schmitt, Marie-Christine Étienne-Grimaldi, Céline Narjoz, Fabienne Thomas, (unknown)	15
7	Artificial increase of uracilemia during fluoropyrimidine treatment can lead to DPD deficiency misinterpretation 2021 ·Annals of Oncology ·Fabienne Thomas, (unknown), Manon Launay, Camille Tron, Marie-Christine Étienne-Grimaldi, Elodie Gautier‐Veyret, Vincent Haufroid, Nicolas Pallet, Bernard Royer, Céline Narjoz, Antonin Schmitt	11
8	Population pharmacokinetic and pharmacodynamic modeling of capecitabine and its metabolites in breast cancer patients 2021 ·Cancer Chemotherapy and Pharmacology ·(unknown), Marie-Christine Étienne-Grimaldi, (unknown), Fabienne Thomas, Florence Dalenc, Jean-Marc Ferrero, Xavier Pivot, G. Milano, Bernard Royer, Antonin Schmitt	6
9	Exposure‐response analysis of Raltitrexed assessing liver toxicity 2020 ·British Journal of Clinical Pharmacology ·Bernard Royer, Antonin Schmitt, Thierry Nguyen, (unknown), Marine Jary, Martin Demarchi, Déwi Vernerey, Julie Henriques, Marion Jacquin, Christophe Borg, Stéfano Kim	4
10	CD4 T cells target colorectal cancer antigens upregulated by oxaliplatin 2019 ·International Journal of Cancer ·Jeanne Galaine, Célia Turco, Charline Vauchy, Bernard Royer, (unknown), (unknown), Romain Loyon, (unknown), Romain Boidot, Caroline Laheurte, Zaher Lakkis, Marine Jary, Olivier Adotévi, Christophe Borg, Yann Godet	36
11	A simple and fast LC–MS/MS method with a very high sensitivity for the measurement of raltitrexed in human plasma 2017 ·Journal of Chromatography B ·Stéfano Kim, (unknown), Damien Montange, (unknown), Thierry Nguyen, Marine Jary, Marion Jacquin, (unknown), Christophe Borg, Bernard Royer	3
12	Continuum of hepatitis C care in France: A 20-year cohort study 2017 ·PLoS ONE ·(unknown), Frédéric Dubois, Catherine Gaudy‐Graffin, Yannick Bacq, Bernard Royer, Christophe Gaborit, Louis d’Altéroche, (unknown), Philippe Roingeard, Leslie Grammatico‐Guillon	1
13	Protective effect of intra-peritoneal epinephrine on postoperative renal function after cisplatin-based intra-peritoneal intra-operative chemotherapy 2011 ·European Journal of Obstetrics & Gynecology and Reproductive Biology ·Sébastien Pili‐Floury, Bernard Royer, (unknown), (unknown), (unknown), Jean‐Marc Chalopin, Xavier Pivot, Bruno Heyd, Bruno Chauffert, Emmanuel Samain	4
14	Population pharmacokinetics of the humanised monoclonal antibody, HuHMFG1 (AS1402), derived from a phase I study on breast cancer 2010 ·British Journal of Cancer ·Bernard Royer, (unknown), Mark D. Pegram, Nuhad K. Ibrahim, (unknown), (unknown), Fredrik Erlandsson, Xavier Pivot	11
15	Niveau de preuve du suivi thérapeutique pharmacologique du cisplatine 2010 ·Therapies ·Anne Hulin, Bernard Royer, Étienne Chatelut, Chantal Le Guellec	3
16	Pharmacokinetic Modelling and Development of Bayesian Estimators for Therapeutic Drug Monitoring of Mycophenolate Mofetil in Reduced-Intensity Haematopoietic Stem Cell Transplantation 2009 ·Clinical Pharmacokinetics ·Franck Saint‐Marcoux, Bernard Royer, Jean Debord, Fabrice Larosa, Faézeh Legrand, Éric Deconinck, Jean‐Pierre Kantelip, Pierre Marquet	29
17	ABCA1 Single Nucleotide Polymorphisms on High‐Density Lipoprotein‐Cholesterol and Overweight: the D.E.S.I.R. Study 2006 ·Obesity ·(unknown), Franck Péan, N. Bellili, Bernard Royer, Joël Cogneau, (unknown), (unknown), Jean Tichet, Beverley Balkau, Michel Marre, Frédéric Fumeron	44
18	Feasibility of using intraperitoneal epinephrine and cisplatin in patients with advanced peritoneal carcinomatosis 2006 ·Anti-Cancer Drugs ·Cécile Moluçon‐Chabrot, Nicolás Isambert, L. Benoît, Sylvie Zanetta, J. Fraisse, Jean-Claude Guilland, Bernard Royer, (unknown), M. Flesch, P. Fargeot, Bruno Coudert, F. Mayer, P. Fumoleau, Bruno Chauffert	12
19	Serum and intraperitoneal pharmacokinetics of cisplatin within intraoperative intraperitoneal chemotherapy: influence of protein binding 2005 ·Anti-Cancer Drugs ·Bernard Royer, Emmanuel Guardiola, (unknown), Guillaume Hoizey, Delphine Delroeux, (unknown), L. Chaigneau, Emmanuel Samain, Bruno Chauffert, Bruno Heyd, Jean‐Pierre Kantelip, Xavier Pivot	37
20	Autocrine regulation of cord blood–derived human mast cell activation by IL-10 2001 ·Journal of Allergy and Clinical Immunology ·Bernard Royer, (unknown), Philippe Saas, (unknown), B Kantelip, Frédéric Féger, Jean‐Jacques Guillosson, Jean‐Pierre Kantelip, Michel Arock	58

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact